How Does Invasive Lobular Differ From Ductal Breast Cancer?

Invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC)—also known as invasive carcinoma of no special type—are the two most common types of breast cancer ^[1]. They behave and grow differently. The main difference is that invasive lobular cancer cells typically grow in a single-file line and spread diffusely through the breast tissue ^[2]. Because of this unique growth pattern, lobular cancer can be harder to see on standard imaging and is more likely to be found in multiple spots within the breast ^[3][4]. However, your overall treatment plan—including surgery, medication, and radiation—will still depend mostly on the cancer’s stage, size, and hormone receptor status, rather than just the structural name of the cancer ^[5].

How Do They Grow Differently?

The cells in your body normally use special proteins to stick together. In most invasive lobular cancers, a gene called CDH1 (a gene that helps make cell-binding proteins) is altered within the tumor itself, causing a reduction or loss of a “molecular glue” protein known as E-cadherin ^[6]. This genetic change is usually acquired just in the cancer cells, not inherited from your parents. Without this glue, lobular cancer cells often do not form a compact mass. Instead, they grow in single-file lines or thin webs that blend into the surrounding breast tissue ^[2].

Invasive ductal carcinoma, on the other hand, usually retains this “glue.” The ductal cancer cells clump together, which is why IDC more frequently feels like a hard lump ^[2]. However, symptoms and imaging alone cannot determine the subtype; both types can form masses or be entirely unnoticeable by touch, and only a biopsy can confirm the diagnosis.

Why Lobular Cancer Can Be Harder to See

Because ILC grows in a diffuse, web-like pattern, it often doesn’t destroy the normal structure of the breast tissue right away. Instead of a distinct lump, you or your doctor might only feel a subtle thickening or fullness ^[3]. While the upper-outer quadrant is a common location for breast tissue and breast cancers generally, lobular cancer can occur anywhere in the breast, and any new change should be checked.

This growth pattern also makes lobular cancer trickier to spot on standard imaging tests:

• Mammograms: Standard digital mammograms can miss ILC or underestimate how large the cancer is because the single-file cells can look like normal breast tissue ^[3][7]. Lobular cancer is more likely to show up as an asymmetry or architectural distortion (a subtle pulling or puckering of the tissue) rather than a clear white mass ^[8].
• 3D Mammography (Tomosynthesis): Adding 3D mammography improves the ability of radiologists to detect the subtle architectural distortions often caused by lobular cancer ^[9].
• Ultrasound: Targeted ultrasound can often find lobular cancers that a mammogram misses, but like a mammogram, it can still underestimate the true size of the tumor ^[7][10].

In addition, lobular cancer has a higher tendency to be multifocal (having more than one area of cancer in the same section of the breast) or multicentric (having cancer in different sections of the breast) ^[4]. Some studies suggest it may also have a slightly higher chance of occurring in both breasts at the same time, though the difference compared to ductal cancer is generally small ^[4][11].

When Is a Breast MRI Useful?

Because standard imaging can underestimate the size of lobular cancer, doctors may consider or recommend a breast MRI (Magnetic Resonance Imaging) ^[12]. An MRI is highly sensitive and is often better at showing the extent of an ILC tumor, though it is not automatically needed for everyone and can sometimes overestimate the size ^[12][10]. It is particularly useful for checking if there are additional areas of cancer in the affected breast or checking the opposite breast ^[13].

However, MRI has limitations. It has a high rate of “false positives,” meaning it often highlights suspicious areas that turn out to be completely benign (not cancer) ^[14]. If an MRI shows new areas of concern, your care team will likely recommend a “second-look” targeted ultrasound. If the area still looks suspicious, they will perform a biopsy (sometimes using MRI guidance if it can’t be seen on ultrasound) to confirm whether it is actually cancer before making major changes to your surgical plan ^[14].

Does the Type Change My Surgery or Treatment?

The word “lobular” or “ductal” (your histologic type) describes what the cells look like under a microscope, but it does not completely dictate your treatment plan. Your surgery and systemic treatments (medications that travel through your body, like hormone-blocking pills or chemotherapy) are guided by the specific biology, receptors, and stage (how far the cancer has progressed and spread) of the tumor ^[5].

• Surgery: You and your surgeon will discuss the choice between a lumpectomy (breast-conserving surgery) and a mastectomy. This decision is not based on histology alone; it depends on the tumor’s size, your breast size, whether the cancer is multifocal, whether you can receive radiation therapy, your genetic risk, and your personal preferences ^[15]. A successful lumpectomy requires clear margins—meaning no cancer cells are touching the inked outer edge of the removed tissue. Because of its diffuse growth, lobular cancer can sometimes require a second surgery to achieve clear margins ^[16]. However, when treated appropriately with radiation and systemic therapy, local recurrence rates after a lumpectomy are similar for both lobular and ductal cancers ^[16][5].
• Systemic Treatment: Most invasive lobular cancers are hormone-receptor positive (meaning they are fueled by estrogen or progesterone) and HER2-negative (lacking a protein that drives fast growth) ^[17]. For hormone-receptor-positive cancers, endocrine (hormone-blocking) therapies reduce the risk of recurrence and are a cornerstone of treatment, though the specific drug and duration depend on your menopausal status, risk level, and side-effect preferences ^[18]. Chemotherapy or targeted HER2 therapies may also be recommended based on your tumor’s stage, lymph node status, and sometimes genomic test scores (tests that look at the activity of genes in the tumor to predict recurrence), not just whether it is lobular or ductal ^[19].